TORONTO, August 24, 2022 /CNW/ – Nurosene Health Inc.. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company focused on developing AI-Healthtech solutions for the health and wellness, neurodegeneration and oncology, appoints neurosurgeons, Douglas James (DJ) Cook as Chief Medical Officer.
DJ Cook MD, PhD is a neurosurgeon and neuroscientist at Queen’s University where he is Division Chief and Chair of Neurosurgery. Dr. Cook earned his MD, Ph.D., and residency at University of Toronto and completed additional training at Stanford University in cerebrovascular and skull base surgery. Dr. Cook’s current research is focused on the development of predictive imaging, physiological and behavioral biomarkers in stroke and traumatic brain injury. His work includes the use of multi-sequence MRI scans using artificial intelligence algorithms to gain new insights into disease mechanisms and to monitor recovery and therapy. Throughout his career, Dr. Cook has used research methodologies to validate and model therapeutic strategies in stroke and traumatic brain injury with numerous industry partners. This work has led to the refinement and/or translation of new therapies into clinical trials. His work has been published in numerous peer-reviewed journals, including Nature and Science Translational Medicine. He holds peer-reviewed funding from NSERC and CIHR.
“Dr. Cook’s experience will play a central role in the development and deployment of the Nuro app and our Netra AI technology. We continue to demonstrate our commitment to the evolution of our leadership team with the key people needed to help us achieve our company goals. We are honored to have Dr. Cook join our leadership team. – CEO of Nurosene, Georges Achilleos.
“I look forward to working with Nurosene in the further development of analytic capabilities and user experience for the Nuro app and Netramark technology to inform new insights from user-derived data. exciting to work with a team that includes several innovative minds from a diverse academic and industrial background,” said Dr Cook.
“The addition of Dr. Cook will significantly increase our capabilities to deliver a superior product experience to our customers, particularly in the pharmaceutical space.” says dr. Joseph GeraciCSO of Nurosene and founder of NetraMark.
Nurosene is a company focused on the development of AI-Healthtech solutions for the health and wellness, neurodegeneration and oncology markets. We have developed an ecosystem of innovative products that directly support brain-related conditions. Our world-renowned team and partners are disrupting traditional mental wellness treatments and positioning themselves at the forefront of critical research and innovation. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., provides proprietary next-generation AI solutions to pharmaceutical and biotech companies across the spectrum of disease.
This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements regarding Dr. Cook’s role in the development of the Nuro application and Netra AI technology, its analysis and its user experience, as well as our ability to provide superior service. product experience to customers that are based on Nurosene’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”. “, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variants thereof, or statements that certain events or conditions “could”, “would” or “will” occur, or through strategy discussions. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, objectives, directions or other statements that are not statements of fact. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all of these factors.
When reviewing these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements contained in Nurosene’s final long form prospectus dated May 20, 2021 and management report for the year ended September 30, 2021 (“MD&A”), and filed with the applicable Canadian securities authorities on SEDAR at www.sedar.com. The risk and other factors set forth in Nurosene’s final long form prospectus and MD&A could cause actual events or results to differ materially from those described in the forward-looking information.
CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Nurosene Health Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2022/24/c3652.html